Clinical Trial Update: Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating daily oral clofarabine given for five days in adults with refractory solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Clofarabine (clofarabine)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED